Sept. 6, 2012
-- Histone deacetylase 6 (HDAC6) is mainly a cytoplasmic enzyme that regulates many important biological processes, including cell migration, immune synapse formation, viral infection, and the degradation of misfolded proteins. HDAC6 deacetylates tubulin, Hsp90 and cortactin, forms complexes with other partner proteins and deacetylates the core histones (H2A, H2B, H3, H4). Consequently, HDAC6 plays an important role in microtubule-
dependent cell motility, transcriptional regulation and cell cycle. These diverse functions of HDAC6 suggest that it is a potential therapeutic target for the treatment of spinal cord injury, autoimmunity, cancer, and many neurodegenerative conditions. Histone deacetylase inhibitors (HDIs) have a long history of use in psychiatry and neurology as mood stabilizers and anti-epileptics and recently as treatment for neurodegenerative disease and cancer therapy. HDAC inhibitors are proposed to work by epigenetic mechanisms, but have effects on non-histone proteins that are related to acetylation as well. HDIs have been shown to alter the activity of many transcription factors, including ACTR, cMyb, E2F1, EKLF, FEN 1, GATA, HNF-4, HSP90, Ku70, NFkB, PCNA, p53, RB, Runx, SF1 Sp3, STAT, TFIIE, TCF, YY1.
BioVision is very pleased to announce the addition of its new, highly selective HDAC6 inhibitor called Nexturastat A to its growing list of HDAC inhibitors.